Exhibit 99.1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
TO CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2021
|
REVIVA PHARMACEUTICALS HOLDINGS, INC. |
|
(Exact name of registrant as specified in its charter) |
|
Delaware |
|
001-38634 |
|
85-4306526 |
|
(State or other jurisdiction
|
|
(Commission File Number) |
|
(IRS Employer
|
|
19925 Stevens Creek Blvd., Suite 100, Cupertino, CA |
|
95014 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (408) 501-8881
|
Not Applicable |
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
RVPH |
|
Nasdaq Capital Market |
|
Warrants to purchase one share of Common Stock |
|
RVPHW |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 8.01. |
Other Events. |
On March 4, 2021, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to use at upcoming investor conferences. A copy of the Investor Presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.
On March 4, 2021, the Company announced that it will be presenting at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.
A copy of the press release that discusses this matter is filed as Exhibit 99.2 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
99.1 |
|
|
|
99.2 |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
REVIVA PHARMACEUTICALS HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Laxminarayan Bhat |
|
|
|
Name: Laxminarayan Bhat |
|
|
|
Title: Chief Executive Officer |
|
|
|
|
|
Dated: March 4, 2021 |
|
|
Exhibit 99.1
Exhibit 99.2
|
PRESS RELEASE |
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
Cupertino, Calif., March 4, 2021 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva”) today announced that its wholly owned subsidiary Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, will present at the H.C. Wainwright Global Life Sciences Conference, which is being held virtually March 9-10, 2021. A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on Tuesday, March 9, 2021.
About Reviva
Reviva is a clinical stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Reviva also intends to develop RP5063 for treating PAH and IPF. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound in clinical development.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Reviva’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Reviva’s expectations with respect to future performance and anticipated financial impacts of the Business Combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Reviva and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the inability to maintain the listing of Reviva’s common stock on NASDAQ; (2) the inability of Reviva to grow and manage growth economically and hire and retain key employees; (3) the risks that Reviva’s products in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities; (4) the risks that Reviva could be forced to delay, reduce or eliminate its planned clinical trials or development programs; (5) changes in applicable laws or regulations; (6) the possibility that Reviva may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties identified in the registration statement on Form S-1 filed by Tenzing with the U.S. Securities and Exchange Commission (the “SEC”) on December 29, 2020, as amended, which became effective on January 11, 2021, including those under the heading “Risk Factors” therein, and in other filings with the SEC made by Reviva Holdings (or previously Tenzing). The foregoing list of factors is not exclusive. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Reviva does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law.
|
|
PRESS RELEASE |
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
(929) 469-3859
bmackle@lifesciadvisors.com